Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xencor (XNCR)

Xencor to receive $105 million from Alexion to settle Ultomiris U.S. royalty dispute

Positive Impact 4 of 5 legal/regulatory Written later

Xencor entered a settlement agreement with Alexion that resolves a dispute over U.S. royalties on Ultomiris, with Xencor to receive $105 million in two equal payments. Alexion will have no further obligation to pay royalties on U.S. sales, while ex-U.S. royalties are unchanged. Xencor said that, based on current operating plans, it expects cash to fund research and development programs and operations through 2028.

Key points

  • Total payment of $105 million, in two $52.5 million installments
  • First $52.5 million payment anticipated in August 2026; second payment due within 14 days after the one-year anniversary of the agreement
  • Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris; ex-U.S. royalties are unchanged
  • Cash runway expected through 2028; year-end 2026 cash guidance to be updated with second-quarter 2026 results

The filing

CompanyXencor (XNCR)
Form8-K, current report
Filed with the SECJul 29, 2026, 4:05 PM ET
Accession number0001326732-26-000049

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.